Search: 
You do not have permission to access this chart.
Please Sign Up or Login
News for Ascendis Pharma A/S (ASND)
Newly released Crypto mining rig for Ascendis Pharma A/S coins
minutes ago | Banggood.com
Everything Crypto on sale now!
58 minutes ago | Aliexpress.com
Ascendis Pharma A/S Announces Upcoming Investor Presentations in August
a week ago | GlobeNewsWire
Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension
2 months ago | Zacks Investment Research
Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months
2 months ago | Benzinga
Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency
2 months ago | GlobeNewsWire
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
2 months ago | PRNewsWire
What 5 Analyst Ratings Have To Say About Ascendis Pharma
2 months ago | Benzinga
Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021
2 months ago | GlobeNewsWire
Ascendis Pharma A/S Reports First Quarter 2021 Financial Results
2 months ago | GlobeNewsWire
Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27
2 months ago | GlobeNewsWire
Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan
3 months ago | GlobeNewsWire

About:

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

482

Address:

Ascendis Pharma A/S Tuborg Boulevard 12 Hellerup 2900 Denmark

Website:

http://www.ascendispharma.com

Phone:

45 70 22 22 44

Leave a comment

Your email address will not be published. Required fields are marked *